{{Drugbox
| Verifiedfields = changed
| Watchedfields = changed
| verifiedrevid = 457636529
| IUPAC_name = (11β,16α)-9,21-dichloro-11-hydroxy-16-methyl-3,20-dioxopregna-1,4-dien-17-yl 2-furoate
| image = Mometasone furoate.svg
| image2 = Mometasone furoate ball-and-stick.png

<!--Clinical data-->
| tradename = Many<ref name=brands2016/>
| Drugs.com = {{drugs.com|monograph|mometasone_furoate}}
| pregnancy_US = C
| legal_US = Rx-only
| routes_of_administration = Topical, inhalation

<!--Pharmacokinetic data-->
| bioavailability = Nasal spray is virtually undetectable in plasma; but systemic availability is comparable to [[fluticasone]]<ref>{{cite journal | title = Pharmacokinetic/pharmacodynamic evaluation of urinary cortisol suppression after inhalation of fluticasone propionate and mometasone furoate |author1=Zia R. Tayab |author2=Tom C. Fardon |author3=Daniel K. C. Lee |author4=Kay Haggart |author5=Lesley C. McFarlane |author6=Brian J. Lipworth |author7=Günther Hochhaus  |last-author-amp=yes | journal = Br J Clin Pharmacol |date=November 2007 | volume = 64 | issue = 5 | pages = 698–705 | doi = 10.1111/j.1365-2125.2007.02919.x | pmid = 17509041 | pmc = 2203259}}</ref>
| protein_bound = 98% to 99%
| metabolism = [[Liver|Hepatic]]
| elimination_half-life = 5.8 hours

<!--Identifiers-->
| CAS_number_Ref = {{cascite|correct|??}}
| CAS_number = 105102-22-5
| CAS_supplemental = {{CAS|83919-23-7}}

| UNII_Ref = {{fdacite|changed|FDA}}
| UNII = 8HR4QJ6DW8

| ATC_prefix = D07
| ATC_suffix = AC13
| ATC_supplemental = {{ATC|R01|AD09}}, {{ATC|R03|BA07}}
| PubChem = 441336
| DrugBank_Ref = {{drugbankcite|changed|drugbank}}
| DrugBank = 
| ChemSpiderID_Ref = {{chemspidercite|correct|chemspider}}
| ChemSpiderID = 390091
| ChEBI_Ref = {{ebicite|correct|EBI}}
| ChEBI = 47564
| ChEMBL_Ref = {{ebicite|correct|EBI}}
| ChEMBL = 1161

<!--Chemical data-->
| chemical_formula = C<sub>22</sub>H<sub>28</sub>Cl<sub>2</sub>O<sub>4</sub> for Mometasone<br> C<sub>27</sub>H<sub>30</sub>O<sub>6</sub>Cl<sub>2</sub> as Furoate
| molecular_weight = 427.361 g/mol (Mometasone) <br> 521.4 g/mol (Furoate)
| SMILES = O=C(O[C@]2(C(=O)CCl)[C@H](C)C[C@H]3[C@@H]4CCC\1=C\C(=O)\C=C/[C@]/1(C)[C@@]4(Cl)[C@@H](O)C[C@]23C)c5occc5
| StdInChI_Ref = {{stdinchicite|correct|chemspider}}
| StdInChI = 1S/C27H30Cl2O6/c1-15-11-19-18-7-6-16-12-17(30)8-9-24(16,2)26(18,29)21(31)13-25(19,3)27(15,22(32)14-28)35-23(33)20-5-4-10-34-20/h4-5,8-10,12,15,18-19,21,31H,6-7,11,13-14H2,1-3H3/t15-,18+,19+,21+,24+,25+,26+,27+/m1/s1
| StdInChIKey_Ref = {{stdinchicite|correct|chemspider}}
| StdInChIKey = WOFMFGQZHJDGCX-ZULDAHANSA-N
| synonyms = <small>(9''R'',10''S'',11''S'',13''S'',14''S'',16''R'',17''R'')-9-chloro-17-(2-chloroacetyl)-11-hydroxy-10,13,16-trimethyl-3-oxo-6,7,8,9,10,11,12,13,14,15,16,17-dodecahydro-3''H''-cyclopenta[''a'']phenanthren-17-yl furan-2-carboxylate</small>
}}

'''Mometasone furoate''' is a [[glucocorticoid]] or [[corticosteroid]] used [[topical medication|topically]] to reduce [[inflammation]] of the [[skin]] or in the [[airway]]s. It is a [[prodrug]] of the free form [[mometasone]] ([[International Nonproprietary Name|INN]]).

==Uses==
Mometasone furoate is used in the treatment of inflammatory skin disorders (such as [[eczema]] and [[psoriasis]]) (topical form), [[allergic rhinitis]] (such as [[hay fever]]) (topical form), [[asthma]] (inhalation form)<ref name="pmid19337427">{{cite journal |vauthors=Tan RA, Corren J |title=Mometasone furoate in the management of asthma: a review |journal=Ther Clin Risk Manag |volume=4 |issue=6 |pages=1201–8 |date=December 2008 |pmid=19337427 |pmc=2643101 |doi= |url=}}</ref><ref name="pmid19392928">{{cite journal |author=Bousquet J |title=Mometasone furoate: an effective anti-inflammatory with a well-defined safety and tolerability profile in the treatment of asthma |journal=Int. J. Clin. Pract. |volume=63 |issue=5 |pages=806–19 |date=May 2009 |pmid=19392928 |doi=10.1111/j.1742-1241.2009.02003.x |url=http://www3.interscience.wiley.com/resolve/openurl?genre=article&sid=nlm:pubmed&issn=1368-5031&date=2009&volume=63&issue=5&spage=806}}</ref> for patients unresponsive to less potent [[corticosteroids]], and penile [[phimosis]].<ref name="pmid20371899">{{cite journal |author=Khope S |title=Topical mometasone furoate for phimosis |journal=Indian Pediatr |volume=47 |issue=3 |pages=282 |date=March 2010 |pmid=20371899 |pmc= |doi= |url=}}</ref> In terms of steroid strength, it is more potent than [[hydrocortisone]], and less potent than [[dexamethasone]].<ref>{{cite journal|last1=Williams|first1=DM|title=What does potency actually mean for inhaled corticosteroids?|journal=The Journal of asthma : official journal of the Association for the Care of Asthma|date=2005|volume=42|issue=6|pages=409–17|pmid=16293535|doi=10.1081/jas-57878}}</ref>

Some low-quality evidence suggests the use of mometasone for symptomatic improvement in children with [[adenoid hypertrophy]].<ref name=nasal2016rev>{{cite journal|last1=Passali|first1=D|last2=Spinosi|first2=MC|last3=Crisanti|first3=A|last4=Bellussi|first4=LM|title=Mometasone furoate nasal spray: a systematic review.|journal=Multidisciplinary respiratory medicine|date=2 May 2016|volume=11|pages=18|pmid=27141307|pmc=4852427|doi=10.1186/s40248-016-0054-3}}</ref>

Mometasone is used to alleviate inflammation and itchiness in skin conditions that respond to treatment with glucocorticoids such as psoriasis and atopic dermatitis<ref>{{cite journal|last1=Green|first1=C|last2=Colquitt|first2=JL|last3=Kirby|first3=J|last4=Davidson|first4=P|last5=Payne|first5=E|title=Clinical and cost-effectiveness of once-daily versus more frequent use of same potency topical corticosteroids for atopic eczema: a systematic review and economic evaluation.|journal=Health technology assessment (Winchester, England)|date=November 2004|volume=8|issue=47|pages=iii, iv, 1–120|pmid=15527669|url=https://www.ncbi.nlm.nih.gov/pubmedhealth/PMH0015083/|doi=10.3310/hta8470}}</ref><ref>{{cite journal|last1=Prakash|first1=A|last2=Benfield|first2=P|title=Topical mometasone. A review of its pharmacological properties and therapeutic use in the treatment of dermatological disorders.|journal=Drugs|date=January 1998|volume=55|issue=1|pages=145–63|pmid=9463794|doi=10.2165/00003495-199855010-00009}}</ref>

Nasal mometasone is used in adults (including the elderly) and children over 2 years to diminishing the symptoms such as hay fever (seasonal allergic rhinitis) and other allergies (perennial rhinitis), including nasal congestion, discharge, pruritus, and sneezing and to treat [[nasal polyps]].<ref name=USlabel/>

=== Asthma ===
Mometasone furoate  can be used with formoterol for the treatment of asthma, due to its anti-inflammatory properties.<ref name=nasal2016rev/><ref>{{cite journal|last1=Bousquet|first1=J|title=Mometasone furoate: an effective anti-inflammatory with a well-defined safety and tolerability profile in the treatment of asthma.|journal=International journal of clinical practice|date=May 2009|volume=63|issue=5|pages=806–19|pmid=19392928|doi=10.1111/j.1742-1241.2009.02003.x}}</ref>

==Pharmacodynamics==
It reduces inflammation by causing several effects:<ref name=USlabel>{{cite web|title=Nasonex label|url=http://www.accessdata.fda.gov/drugsatfda_docs/label/2011/020762s044lbl.pdf|publisher=FDA|date=January 2011}}</ref><ref>{{Cite book |url=https://books.google.com/books?id=9b8JiegivA8C&pg=PA677 |page=677 |author1=Publishers, Jones and Bartlett |date=2009-07-15 |isbn=978-0-7637-7900-9 |title=Nurse's Drug Handbook 2010 |postscript=<!--None-->}}</ref><ref>{{Cite book |title=Diagnosis and Management of Asthma |author=Mani S. Kavuru |chapter=ch. 9 Anti-inflammatory agents |url=https://books.google.com/books?id=Q1zF7xSRACIC |year=2007 |isbn=978-1-932610-38-3 |postscript=<!--None-->}}</ref>
* Reversing the activation of inflammatory proteins
* Activating the secretion of anti-inflammatory proteins
* Stabilizing cell membranes
* Decreasing the influx of inflammatory cells

In addition to the [[glucocorticoid]] properties of mometasone furoate, it is a very potent [[agonist]] of the [[progesterone receptor]] as well as a [[partial agonist]] of the [[mineralocorticoid receptor]].<ref name="pmid12503693">{{vcite2 journal | vauthors = Austin RJ, Maschera B, Walker A, Fairbairn L, Meldrum E, Farrow SN, Uings IJ | title = Mometasone furoate is a less specific glucocorticoid than fluticasone propionate | journal = Eur. Respir. J. | volume = 20 | issue = 6 | pages = 1386–92 | year = 2002 | pmid = 12503693 | doi = 10.1183/09031936.02.02472001| url = }}</ref>

==Mechanism of action==
[[File:Mometasone.svg|thumb|left|Mometasone — the metabolite of mometasone furoate]]
Mometasone, like other corticosteroids, possesses anti-inflammatory, antipruritic, and vasoconstrictive properties. For allergies, corticosteroids reduce the allergic reactions in various types of cells (mastocytes and eosinophils) that are responsible for allergic reactions. Mometasone and other corticosteroids circulate in the blood easily, crossing cellular membranes and binding with cytoplasmic receptors, resulting in the transcription and synthesis of proteins. It also inhibits the actions of the enzyme [[CYP2C8|cytochrome P450 2C8]] which participates in the activity of monooxygenase.<ref>{{cite book|last=Walsky|first=R. L.|author2=Gaman EA |author3=Obach RS. |title=Examination of 209 drugs for inhibition of cytochrome P450 2C8.|publisher=J Clin Pharmacol.| date=Jan 2005 |volume=45|number=1|pages=68–78|pmid=15601807|edition=Pfizer Global Research and Development|location=USA.|section=Pharmacokientics, Pharmacodynamics, and Drug Metabolism}}</ref>

The inflammation is reduced in decreasing the liberation of hydrolace acids of leukocytes, the prevention of the accumulation macrophages in the sites of inflammation, the interference with adhesion of leukocytes to capillary walls, the reduction of the permeability of the capillary membranes and consequently edema, the reduction of complementary components, inhibition of histamine and kinin liberation, and interference with scar tissue formation.<ref>{{cite journal|last1=Blaiss|first1=MS|title=Safety update regarding intranasal corticosteroids for the treatment of allergic rhinitis.|journal=Allergy and Asthma Proceedings|date=2011|volume=32|issue=6|pages=413–8|pmid=22221434|doi=10.2500/aap.2011.32.3473}}</ref> The proliferation of fibroblasts and collagen deposits are also reduced. It is believed that the action of corticosteroid anti-inflammatory agents are bound to inhibitive proteins of [[phospholipase A2]], collectively called lipocortins. The lipocortins, in turn, control the biosynthesis of potent mediators of inflammation as the [[prostaglandin]]s and [[leukotriene]]s, inhibiting the liberation of the molecular precursors of [[arachidonic acid]]. Intranasal mometasone alleviates symptoms such as [[rhinorrhea]] aquosa, [[nasal congestion]], nasal drip, sneezing, and pharyngeal itching. Topical administration applied to skin reduces the inflammation associated with chronic or acute dermatosis.

== Metabolism ==
Extensive metabolic hepatic metabolism to multiple metabolites occurs. No principal metabolites are detectable in plasma. After ''in vitro'' incubation, one of the minor metabolites formed is furoate 6β-hydroxymometasone. In human hepatic microsomes, the formation of these metabolites is regulated by [[CYP3A4]].<ref name=USlabel/>

==Brands==
As of 2016 mometasone furoate was available worldwide in formulations for nasal, oral inhalation, and topical administration, for human and for veterinary use, and in combinations with other drugs, under many brand names.<ref name=brands2016>{{cite web|title=International brands for Mometasone|url=https://www.drugs.com/international/mometasone.html|publisher=Drugs.com|accessdate=17 November 2016}}</ref>

The following combination drugs were available as of 2016:<ref name=brands2016/>
* Mometasone and [[azelastine]] as Nasaflex
* Mometasone and [[clotrimazole]] and [[gentamicin]] for veterinary use as Mometamax
* Mometasone and [[florfenicol]] and [[terbinafine]] for veterinary use as Claro
* Mometasone and [[formoterol]] as Dulera and Zenhale
* Mometasone and [[fusidic acid]] as Momate-F
* Mometasone and [[miconazole]] as Elica M and Sensicort-F
* Mometasone and [[mupirocin]] as Sensicort-B
* Mometasone and [[orbifloxacin]] and [[posaconazole]] for veterinary use as Posatex
* Mometasone and [[salicylic acid]] as Belosalic, Cortimax-S, Elicasal, Elocom Plus, Elosalic, Momate, Momesalic, Momtas, Monsalic, and Sensicort-S
* Mometasone and [[tazarotene]] as Tazasone Forte
* Mometasone and [[terbinafine]] as Cutizone-T

It was available as of 2016 as the single active agent in the following brands:  Alcom, Altosone, Asmanex, Atozon, Aureox, Belloseta, Bioelementa, Biometasona, Bloctimo, Borgasone, Breso, Broner, Codermo, Cortynase, Cutimom, Cutizone, Cutticom, Dance, Demoson, Dergentil, Derimod, Dermacortine, Dermaten, Dermome, Dermosona, Dermotasone, Dermovel, Desdek, Ecelecort, Ecural, Edelan, Elica, Elisone, Elisox, Elitasone, Elna, Elocan, Elocom, Elocon, Elocortin, Elofute, Elomet, Elomox, Eloskin, Eloson, Elosone, Elovent, Elox, Etacid, Eversone, Eztom, F-Din, Fenisona, Flazcort, Flogocort, Fremomet, Frondava, Fu Mei Song, Fulmeta, Furo, Furoato de Mometasona, Furoderm, Gistan-H, Honmet, Iflacort, Intercon, Ivoxel, Kalmente, Konex, Ladexol, Lisoder, Logren, Loksin, Lomeane, M-Furo, Makiren, Mefurosan, Melocort, Mena, Mesone, Metacortil, Metactiv, Metaflam, Metagra, Metasafe, Metason, Metasone, Metaspray, Metatop, Metaz, Metmin, Metsone, Midermin, Mifusin, Minyear, Mofacort, Mofulex, Mofur, Mofuroate, Molison, Momate, Momax, Momecon, Momecort, Momecutan, Momederm, MomeGalen, Momegen, Momekort, Momelab, Momentum, Momeplus, Momerid, Momeson, Momesone, Momester, Momet, Mometa, Mometagen, Mometason, Mometasona, Mometasona Furoato, Mometasone Furoate, Mometasone Furoate Hydrate, Mometasonfuroaat, Mometasonfuroat, Mometasoni furoas, Mometasonum, Mometasyn, Mometasyn, Mometax, Mometazon, Mometazona, Mometazona Fuorat, Mometazonfuroat, Mometix-AQ, Momevate, Momexa, Mommex, Mommox, Momtas, Monaliz, Monez, Monovel, Monovo, Mosone, Motaderm, Motaneal, Movesan, Mtaz, Mundoson, Murozo, Myrey, Narinex, Nasamet, Nasehaler, Nasocure, Nasomet, Nasometin, Nasonex, Nassomet, Nazofix, Nazoster, Netonox, Nexomist, Novasone, Ovison, Ovixan, Oximax, Pharmecort, Pluster, Pronasal, Propel, Prospiril, Pydercon, Rinelon, Rinitek, Rino-Val, Rinobudex, Rinonex, Rinosal, Rinosona, Rinoval, Risonel, Sensicort, Septopic, Silkaren, Soneta, Suavicort, Suqi, Synaller, Tabunex, Topcort, Topison, Uniclar, Uniderm, Vizomet, Yperod, Zalconex, and Zynovate.<ref name=brands2016/>

== References ==
{{Reflist|2}}

{{Glucocorticoids}}
{{Nasal preparations}}
{{Glucocorticoidics}}
{{Mineralocorticoidics}}
{{Progestogenics}}

[[Category:Antiasthmatic drugs]]
[[Category:Corticosteroid esters]]
[[Category:Furoates]]
[[Category:Glucocorticoids]]
[[Category:Mineralocorticoids]]
[[Category:Organochlorides]]
[[Category:Pregnanes]]
[[Category:Progestogens]]
[[Category:Schering-Plough]]